Abstract
Acute decompensated heart failure poses a complex clinical challenge for the health care community. Evolving concepts of the pathophysiology and lack of consensus on appropriate outcome measures for drug approval underlie some of the current controversies about nesiritide. We outline the major controversies from the viewpoint that nesiritide should continue to be used judiciously by following its package insert recommendations and the Heart Failure Society of America's 2006 Comprehensive Heart Failure Practice Guidelines.
MeSH terms
-
Acute Disease
-
Evidence-Based Medicine
-
Heart Failure / drug therapy*
-
Heart Failure / mortality
-
Heart Failure / physiopathology
-
Humans
-
Natriuretic Agents / administration & dosage
-
Natriuretic Agents / adverse effects
-
Natriuretic Agents / pharmacology
-
Natriuretic Agents / therapeutic use*
-
Natriuretic Peptide, Brain / administration & dosage
-
Natriuretic Peptide, Brain / adverse effects
-
Natriuretic Peptide, Brain / pharmacology
-
Natriuretic Peptide, Brain / therapeutic use*
-
Outcome Assessment, Health Care / methods
-
Patient Selection
-
Practice Guidelines as Topic
-
Renal Insufficiency
Substances
-
Natriuretic Agents
-
Natriuretic Peptide, Brain